Abbott jumps on RFK Jr. health push — plus, reviews of Eli Lilly’s obesity drug data
Every day during the week, Jim Crammer and CNBC Investment Club released Homestretch, a processable afternoon update at the last hour of trade at Wall Street. Markets: As the geopolitical tensions in the Middle East alleviated and oil prices decreased, the stocks were collected on a second day. The S&P rose by more than 1% on Tuesday and was at the highest level of the session in the afternoon trade. Technology and financial, two major sector winners of the day, chip stocks are rising, and banks are receiving vapor in front of a few highly anticipated organizational events at the end of this week, including the publication of the annual stress test results of the Federal Reserve on Friday. Obesity attempt: The experimental weight loss drug designed to help Eli Lilly’s protection of patients’ muscle mass did not receive Wow Wow. This was our analyst notes that we read Tuesday the day after presenting mid -stage trial data about the drug known as Bimagrumab at Lilly’s annual conference of the American Diabetes Association. As Lilly’s GLP-1 obesity drugs such as Zepbound and Novo Nordisk’s Wegovy gain popularity, some observers expressed their concerns about the amount of muscle mass that patients lost in addition to fat. According to Bernstein analysts, the existing rate is usually 70% fat and 30%, “an important load for patients”. In this question, Bimagrumab data, published on Monday, were often seen positively by the street, and Leerink Partners said that he showed “compelling activity”. Obesity medication is the highest dose of Bimagrumab in addition to the semagludidin, patients lost more fat than semaglud fields -about 93% fat mass compared to 71.5%. Semaglutid is the active ingredient in Wegovy. Tirzepathide is an active ingredient in Lilly’s Zepbound. However, Leerink and other Wall Street companies expressed what it means for tolerability and safety data and its commercial expectations. For this reason, Leerink and Jeferveries analysts said that financial models for Lilly do not contain any sales contribution from Bimagrumab. Wolfe Research, Lilly Stock, while maintaining a better purchase note, the company “security and cutting rates keep us on the sidelines for now,” he said. Wolfe Research is needed for both doctors and investors, “more data is needed to get a better idea of commercial opportunity for this muscle protection drugs class”. The general meaning is that Bimagrumab is used in more targeted populations that muscle loss is a more urgent concern that it will not be prescribed on a large scale. As a note to customers on Tuesday, Bernstein said that it may include elderly patients and perhaps less pound and some patients who need to throw “re -balancing body composition”. “No matter what, there is still a lot to play,” the analysts wrote Wolfe, saying that the data from Lilly’s ongoing trials for the drug would be necessary. For us, we join the street in Bimagrumab – and we focus more on Lilly’s daily obesity pill or the development of Macarglpron. In the third quarter, late -stage trial data is expected to be expected to be for Obit. Wearable: Health and Human Services Secretary Robert F. Kennedy Jr. He said on Tuesday that his department plans to encourage the use of wearable health devices. “My vision is wearing wearable in every four years,” said Rfk Jr. The comments sent the shares of Abbott Laboratoies and other continuous glucose monitor (CGM) device manufacturers. We will need to see all the details when the campaign is released, but Abbott is well positioned to take advantage of the increasing adoption of these devices. Free style is not only available for diabetic patients in Libre, but also has the best -selling CGM, but also has an existing CGM without a prescription in Lingo. Next: Fedex reports earnings after the closing of Tuesday. General Mills reports before the opening bell of Wednesday. The economy has a number of data on Wednesday, including mortgage applications, new home sales and building permits. (See here for the full list of Jim Cramer’s philanthropist’s confidence in the charitable trust. Jim is waiting for 45 minutes after sending a trade warning before buying or selling a share in the portfolio of charitable confidence. If Jim talked about a stock on CNBC TV, he’s waiting for 72 hours after trading warning before trading. The above investment club information is subject to our conditions and conditions and our Privacy Policy with the waiver. There is no confidence or duty or not, as you receive any information provided in connection with the Investment Club. A specific result or profit is not guaranteed.
